Apexigen, Inc. (APGN) Stock

About Apexigen, Inc.

Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.

Apexigen, Inc. is headquartered in US.

Apexigen, Inc. (APGN) stock trades at $0.39 with a market capitalization of $9.57M. The stock is valued at a price-to-earnings (P/E) ratio of -0.24, price-to-book of 1.19, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.33 and $8.28, and currently trades 95.3% below its 52-week high.

On profitability, Apexigen, Inc. generates a return on equity (ROE) of 48.27% — well above the market average, a sign of a high-quality business, return on capital employed of -511.68%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.apexigen.com